#316
|
||||
|
||||
Ïîäñêàæèòå ïîæàëóéñòà, êàê íàçûâàåòñÿ ÎÀÊ â àíãëîãîâîðÿùèõ ñòðàíàõ.
|
#317
|
|||
|
|||
Complete Blood Count (CBC)
|
#318
|
||||
|
||||
|
#319
|
||||
|
||||
Full Blood Count
Synonyms: FBC, complete blood count (USA), CBC (USA) blood panel - rare |
#320
|
|||
|
|||
"Íàä ñåðäöåì"
Äîáðûé äåíü,
ÿ ïåðåâîä÷èê ñ íåìåöêîãî è â òåêñòå ó ìåíÿ âñòðåòèëàñü ñëåäóþùàÿ ôðàçà: Über dem Herzen Systolikum über der Aorta, regelmäßige Aktion. Åñëè ïåðåâîäèòü äîñëîâíî, òî ïîëó÷èòñÿ: Íàä ñåðäöåì ñèñòîëè÷åñêèé øóì íàä àîðòîé, ðàáîòà ðåãóëÿðíàÿ. ß ïåðåâåëà êàê Íàä âåðõóøêîé ñåðäöà ñèñòîëè÷åñêèé øóì íàä àîðòîé, ðèòì ðàáîòû ñåðäöà ðåãóëÿðíûé. Ðåäàêòîð (òîæå íå ìåäèê) èñïðàâèë ìíå âåðõóøêó íà "âåðõíèé îòäåë", ïîëó÷èëîñü: Íàä âåðõíèì îòäåëîì ñåðäöà ñèñòîëè÷åñêèé øóì íàä àîðòîé, ðèòì ðàáîòû ñåðäöà ðåãóëÿðíûé. È òàêîå ó ìåíÿ îùóùåíèå, ÷òî è ÿ ïåðåâåëà íå ñîâñåì âåðíî, è ÷òî ðåäàêòîð åùå õóæå ñäåëàë. Ïîýòîìó ïðîøó ïîäñêàçàòü, êàê æå ýòî äîëæíî áûòü íà ñàìîì äåëå. |
#321
|
|||
|
|||
"Íàä âåðõóøêîé ñåðäöà" è "íàä àîðòîé" ýòî ðàçíûå ïîçèöèè àóñêóëüòàöèè (âûñëóøèâàíèÿ). "Ðàáîòà ðåãóëÿðíàÿ" òîæå íåÿñíî ê ÷åìó. Ëó÷øå ïðèâåäèòå áîëåå ïîëíóþ ÷àñòü òåêñòà.
ÇÛ. Ó íàñ åñòü ñïåöèàëüíàÿ òåìà äëÿ òðóäíîñòåé ñ ïåðåâîäîì. Ïåðåíåñó âñå òóäà. |
#322
|
|||
|
|||
Öèòàòà:
Åñëè áóêâàëüíî, òî òàì "íàä ñåðäöåì ñèñòîëè÷åñêèé øóì íàä àîðòîé". ß ïîíÿëà ýòî "íàä ñåðäöåì" êàê "íàä âåðõóøêîé ñåðäöà", íî àîðòà, êîíå÷íî, - ýòî íå âåðõóøêà. "Ðàáîòà ðåãóëÿðíàÿ" - î ðèòìå ÿâíî. À ãäå òåìà äëÿ òðóäíîñòåé ñ ïåðåâîäîì? ß íå íàøëà, ïîýòîìó è ðàçìåñòèëà çäåñü. |
#323
|
|||
|
|||
#324
|
|||
|
|||
#325
|
|||
|
|||
Íó ìíå òàê ïîíÿòíî, ÷òî "íàä àîðòîé âûñëóøèâàåòñÿ ñèñòîëè÷åñêèé øóì". Êàê òî÷íåå, "íàä àîðòîé" èëè " íà àîðòå", ìîæåò êàðäèîëîãè äîïîëíÿò.
|
#326
|
|||
|
|||
"Über dem Herzen" â ìîåì ïîíèìàíèè - "íà îñíîâàíèè ñåðäöà" (îñíîâàíèå ñåðäöà - ýòî êàê ðàç "íàä ñåðäöåì", ò.å. àîðòà è ëåãî÷íûé ñòâîë
"Systolikum über der Aorta" - ñèñòîëè÷åñêèé øóì íàä àîðòîé, êàê è áûëî ñêàçàíî.  ïðèíöèïå ôðàçà "íà îñíîâàíèè ñåðäöà" çäåñü ëèøíÿÿ, ýòî è òàê ïîíÿòíî (åñëè òîëüêî ãåðìàíöû íå õîòÿò ïîä÷åðêíóòü, ÷òî ýòî èìåííî 2 ì/ð ñïðàâà îò ãðóäèíû, à íå òî÷êà Áîòêèíà-Ýðáà, êîòîðàÿ òîæå ÿâëÿåòñÿ äîïîëíèòåëüíîé òî÷êîé àóñêóëüòàöèè øóìîâ ñ àîðòàëüíîãî êëàïàíà. Ìîæíî ïðîñòî ïåðåâåñòè "ðèòì ïðàâèëüíûé, âûñëóøèâàåòñÿ ñèñòîëè÷åñêèé øóì íàä àîðòîé". Íåäîïîíèìàíèÿ 100% íå âîçíèêíåò. |
#327
|
|||
|
|||
Vlad34, Rodionov, ñïàñèáî îãðîìíîå!
|
#329
|
||||
|
||||
Çäðàâñòâóéòå, óâàæàåìûå.
ïðîøó ïîìîùè â ïåðåâîäå, à èìåííî, êàê ïðàâèëüíî ïåðåâîäÿòñÿ íèæåñëåäóþùèå òåðìèíû íà àíãëèéñêèé ÿçûê:
Ñïàñèáî. |
#330
|
|||
|
|||
Äàâíî òåìà íå çâó÷àëà.
Êàê-òî "çàñòóïîðèëñÿ".. The correlation between KRAS mutations and ORR was expressed as a relative ratio (RR) for ORR of mutant KRAS patients over wild-type KRAS patients. Thus, a RR equal to 1 indicates a lack of association between KRAS mutations and cetuximab treatment; a RR more than 1 corresponds to a direct correlation between higher ORR and KRAS mutations and a tendency of mutant KRAS patients to have worse responsiveness is indicated by a RR less than 1. |